Yondelis trabectedin regulatory update

Johnson & Johnson’s Janssen Research & Development LLC unit submitted an NDA to FDA for Yondelis trabectedin to treat patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy, including an anthracycline. The cytotoxic alkaloid that binds the minor groove of DNA is approved in 76 countries to treat advanced STS and 69 countries for relapsed ovarian cancer. ...